Congenital Adrenal Hyperplasia Clinical Trial
Official title:
Evaluation of Cardiovascular Risk Profile in Adult Patients With Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency Diagnosed During Childhood
Treatment with glucocorticoids and mineralocorticoids has changed congenital adrenal hyperplasia (CAH) from a fatal to a chronic lifelong disease. Long-term treatment, in particular the chronic (over-)treatment with glucocorticoids, may have an adverse effect on the cardiovascular risk profile in adult CAH patients. The objective of this study was to evaluate the cardiovascular risk profile of adult CAH patients.
Treatment with glucocorticoids and mineralocorticoids has changed congenital adrenal
hyperplasia (CAH) from a fatal to a chronic lifelong disease. Long-term treatment, in
particular the chronic (over-)treatment with glucocorticoids, may have an adverse effect on
the cardiovascular risk profile in adult CAH patients. The objective of this study was to
evaluate the cardiovascular risk profile of adult CAH patients.
DESIGN: Case control study Primary objective : detection of cardiovascular damage in
patients with classical or non classical CAH diagnosed in childhood. The patients will be
compared with age- and gender- and tobacco status- matched control.
Secondary objective Study of microvascular function Evaluation of cardiovascular risk
factors Total cumulative (TCG) and total average (TAG) glucocorticoid doses will be
calculated from pediatric and adult files and correlated to arterial macro- and
microcirculatory dysfunction.
Primary outcome Ultrasound evaluation of intima-media thickness at common carotids, carotid
bulbs and left ventricular function Secondary outcome Peripheral and central blood pressure
Skin capillary density and pulse-wave velocity Glucose and insulin during an oral glucose
tolerance test Circulating cardiovascular risk markers (hsCRP, adiponectin, Interleukin-6)
Lipid profile Anthropometry, fat and lean mass measured by dual-energy X-ray absorptiometry
Total cumulative dose of glucocorticoid Number of subjects : 90 patients/90 controls
Inclusion criteria of CAH patients
- Patients > 18 yrs with classical or non classical CAH diagnosed during childhood
- Absence of known cardiovascular disease
- Absence of combined oral contraceptives during the previous month Inclusion criteria of
controls
- Age under 18
- Absence of known cardiovascular disease
- Absence of combined oral contraceptives during the previous month
Duration of the inclusion period: 3 years
;
Observational Model: Cohort, Time Perspective: Cross-Sectional
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03687242 -
Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia
|
Phase 2 | |
| Active, not recruiting |
NCT04544410 -
A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH
|
Phase 2 | |
| Not yet recruiting |
NCT04087148 -
Linear Growth of Children With Congenital Adrenal Hyperplasia
|
||
| Completed |
NCT03162159 -
Adult Height Prediction in Congenital Adrenal Hyperplasia
|
||
| Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
| Enrolling by invitation |
NCT05162950 -
Effects and Importance of Epinephrine/Adrenalin Deficiency in CAH
|
||
| Withdrawn |
NCT03532022 -
Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy
|
Phase 3 | |
| Recruiting |
NCT02795871 -
Prenatal Dex Study
|
N/A | |
| Completed |
NCT02934399 -
Dynamic Hormone Diagnostics in Endocrine Disease
|
||
| Recruiting |
NCT04903587 -
Gonadal Changes In Congenital Adrenal Hyperplasia Patients
|
||
| Not yet recruiting |
NCT04536662 -
Comparisons of Different Forms of Glucocorticoid on the Recovery of Reproductive Function in Patients With 21α-hydroxylase Deficiency
|
Phase 4 | |
| Recruiting |
NCT04463316 -
GROWing Up With Rare GENEtic Syndromes
|
||
| Active, not recruiting |
NCT04490915 -
Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
|
Phase 3 | |
| Completed |
NCT02804178 -
A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
|
Phase 2 | |
| Completed |
NCT03019614 -
An Open Label Study in Healthy Volunteers to Compare Chronocort® to Hydrocortisone
|
Phase 1 | |
| Not yet recruiting |
NCT04293133 -
Final Height in Patients With CAH
|
||
| Recruiting |
NCT03897504 -
Surgical Evaluation of Using the Prepuce in Feminizing Genitoplasty
|
N/A | |
| Recruiting |
NCT05663320 -
A Study of a Virtual Education-Based Transition Intervention to Improve Transition Readiness in Adolescent and Young Adults With Congenital Adrenal Hyperplasia
|
N/A | |
| Active, not recruiting |
NCT04806451 -
Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Patients With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)
|
Phase 3 | |
| Completed |
NCT01875640 -
Decision Support for Parents Receiving Information About Child's Rare Disease
|